Natural History of Treated Neurocysticercosis and Long-Term Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-99
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

About this trial

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care.

Eligibility criteria

Qualifiers

Aged 3 years and older.

Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document.

Patients with proven or likely NCC

Patient with epidemiologic history compatible with possible exposure to NCC

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

500 Participants
are grouped into 6 trial groups

6

Trial groups

See each trial group below.